MedTrace Logo

A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV

NCT04490057 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 323

Last updated 2026-01-05

Study results available
· View outcomes & findings →

Summary

Many people living with HIV (PLWH) smoke. Smoking in these individuals is often undertreated. This study plans to assess the ability of various clinical pathways involving tobacco treatment medications and contingency management (paying smokers for not smoking) to improve smoking cessation in a group of PLWH.

Conditions

  • Tobacco Use Cessation

Interventions

DRUG

Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler

Participants will be prescribed both long-acting and short-acting nicotine replacement therapy.

DRUG

Varenicline or bupropion

Participants will be prescribed varenicline (Chantix) or bupropion (Wellbutrin).

BEHAVIORAL

Contingency Management

Participants will be financially rewarded for abstinence to tobacco.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Yale University

    lead OTHER

Principal Investigators

  • E. Jennifer Edelman, MD, MHS · Yale University

  • Steven Bernstein, MD · Dartmouth College

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-27
Primary Completion
2024-10-24
Completion
2025-10-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04490057 on ClinicalTrials.gov